Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2007, Toronto, Canada, 2007.
Ries, L.A.G., Eisner, M.P., Kosary, C.L., et al. SEER Cancer Statistics Review, 1973-1997. Bethesda, Md: National Cancer Institute; 2000.
Pashos, C.L., Botteman, M.F., Laskin, B.L., et al. Bladder cancer : epidemiology, diagnosis, and management. Cancer Pract. 2002; 10: 311-22.
Logsetty, S. Screening for bladder cancer. In: Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa Health Canada, 1994; 826-36.
World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. 2004.
Reading, J., Hall, R.R., Parmar, M.K.B. The application of a prognostic factor analysis for Ta, T1 bladder cancer in routine urological practice. Br. J. Urol. 1995; 75: 604-7.
Smith, J.A., Labasky, R.F., Cockett, A.T.K., et al. Bladder Cancer Clinical Guidelines Panel summary report on the management of non-muscle invasive bladder cancer (stages Ta, T1 and Tis). J. Urol. 1999; 162: 1697-1701.
Herr, H.W., Schwalb, D.M., Zhang, Z-F., et al. Intravesical bacille Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol. 1995; 13: 1404-8.
Lamm, D.L., Blumenstein, B.A., Crissman, J.D., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J. Urol. 2000; 163: 1124-9.
O’Donnell, M.A., Krohn, J., and DeWolf, W.C. Salvage intravesical therapy with interferon-alpha 2B plus low dose bacillus Calmette-Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guérin alone previously failed. J. Urol. 2001; 166: 1300-4.
Steinberg, G., et al., Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J. Urol. 2000; 163: 761-7.
Lundholm, C., et al., A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J. Urol., 1996; 156: 372-6.
Malmstrom, P.U., et al., 5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J. Urol. 1999; 161: 1124-7.
Lam, J.S., et al., Bacillus Calmette-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol. Oncol. 2003; 21: 354-60
Stein, J.P., Lieskovsky, G., Cote, R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J. Clin. Oncol. 2001; 19: 666-75.
Cooke, P.W., Dunn, J.A., Latief, T., et al. Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer. Eur. Urol. 2000; 38: 279-86.
Gospodarowicz, M.K., Hawkins, N.V., Rawlings, G.A., et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J. Urol. 1989; 14: 1448-53.
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systemic review and meta-analysis of individual patient data. Eur. Urol. 2005; 48: 202-5.
Coppin, C.M., Gospodarowicz, M.K., James, K., Tannock, I.F., Zee, B., Carson, J., et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1996; 14: 2901-7.
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur. Urol. 2005; 48: 189-201.
Shipley, W., Zietman, A., Kaufman, D., et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria invasive bladder cancer and who are cystectomy candidates - The Massachusetts General Hospital and Radiation Therapy Group experiences. Semin. Radiat. Oncol. 2004; 15: 36-41.
Rödel, C., Grabenbauer, G.G., Kühn, R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J. Clin. Oncol. 2002; 20: 3061-71.
van der Maase, H., Hansen, S.W., Roberts, J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicentre, phase III study. J. Clin. Oncol. 2000; 17: 3068-77.
Locke, J.R., Hill, D.E., and Walzer, Y. Incidence of squamous cell carcinomas in patients with long term catheter drainage. J. Urol. 1985; 133: 1034-5.
Jones, M.A., Bloom, H.J.G., Williams, G., et al. The management of squamous cell carcinoma of the bladder. J. Urol. 1980; 52: 511-4.
Serretta, V., Pomara, G., Piazza, F., et al. Pure squamous cell carcinoma of the bladder in Western countries. Eur. Urol. 2000; 37: 85-9.
Swanson, D.A., Liles, A., and Zagars, G.K. Pre-operative irradiation and radical cystectomy for stage T2 and T3 squamous cell carcinoma of the bladder. J. Urol. 1990; 143: 37-40.
Grignon, D.J., Ro, J.Y., Ayala, A.G., et al. Primary adenocarcinoma of the urinary bladder: a clinicopathologic analysis of 72 cases. Cancer 1991; 67: 2165-72.
Siefker-Radtke, A.O., Gee, J., Shen, Y., et al. Multimodality management of urachal carcinoma: the M.D. Anderson experience. J. Urol. 2003; 169: 1295-8.
Blomjour, C.E., Vos, W., De Voogt, H.J., et al. Small cell carcinoma of the urinary bladder: a clinicopathologic, morphologic, immunohistochemical, and ultrastructural study of 18 cases. Cancer 1989; 64: 1347-57.
Lohrisch, C., Murray, N., Pickles, T., et al. Small cell carcinoma of the bladder. Long term outcome with integrated chemoradiation. Cancer 1999; 86: 2346-52.
Walther, P.J. Adjuvant/neoadjuvant etoposide/cisplatin and cystectomy for management of invasive small cell carcinoma. J. Urol. 2002; 167: 285, Abstract 1124.
Kim, J.C., Steinberg, G.D. The limits of bacillus Calmette-Guérin for carcinoma in situ of the bladder. J. Urol. 2001; 165: 745-756.
